Today, the biotechnology sector is witnessing a significant rally, with Compass Pathways (NASDAQ:CMPS) leading the charge. As the company nears the finish line for its Phase 3 clinical trials, a ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that CEO Kabir Nath will ...

LONDON & NEW YORK--(BUSINESS WIRE)-- Compass Pathways plc (CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive ...

Compass PathwaysCMPS stock surged Monday after President Donald Trump signed an executive order to ease the approval journey for psychedelic drugs. The order has two key elements. It provides a speedy ...

A White House Executive Order over the weekend has some healthcare company stocks soaring today. One big winner is Compass Pathways (NASDAQ: CMPS). Shares of the biotechnology company rocketed more ...

Good day, ladies and gentlemen, and welcome to the COMPASS Pathways First Quarter Results Conference Call. [Operator Instructions] As a reminder, this call is being recorded. I would now like to turn ...

Compass Pathways (NASDAQ:CMPS) is one of the small cap stocks with the highest upside potential. On April 24, Compass Pathways announced that the US FDA granted a rolling review for its NDA and ...

Compass Pathways has already reported two positive phase 3 trials for treatment-resistant depression (TRD). The company's COMP360 synthetic psilocybin treatment could now be on a faster track for ...